COVID-19 Clinical Trial
Official title:
A Clinical Trial to Evaluate the Immunogenicity Bridging Between Different Manufacture Scales of Recombinant COVID-19 Vaccine (Sf9 Cell) in Healthy Population Aged 18-59 Years
Verified date | March 2024 |
Source | WestVac Biopharma Co., Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a randomized, double-blind , non-inferiority design study, to evaluate the Immunogenicity bridging between different manufacture scales of Recombinant COVID-19 Vaccine (Sf9 Cell) in healthy population aged 18-59 years with immunization procedures 0, 21, 42 days .
Status | Completed |
Enrollment | 1000 |
Est. completion date | December 30, 2023 |
Est. primary completion date | March 11, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 59 Years |
Eligibility | Inclusion Criteria: - Subjects aged from 18-59 years. - Signed informed consent forms of the subjects have been obtained. - Able and willing to comply with the requirements of the clinical trial protocol and able to complete approximately 8 months of study follow-up. - Axillary temperature < 37.3?. Subjects who fulfill all the required conditions for receiving the candidate vaccine as established by medical history and physical examination and determined by investigators. Exclusion Criteria: - Positive SARS-CoV-2 antibodies (IgG or IgM) screening results. - Positive SARS-CoV-2 Antigen screening results. - History of COVID-19 vaccination. - Previously diagnosed with COVID-19 infection. - History of HIV infection. - History or family history of convulsion, epilepsy, encephalopathy and psychosis. - Allergy to any component of the candidate vaccine, severe allergy to vaccine in the past, and history of allergy. - Women with positive urine pregnancy test results, pregnant, lactating women, or women who have a pregnancy plan during the study. - Patients with acute febrile diseases and infectious diseases. - Patients with a history of SARS. - Serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension that cannot be controlled by drugs, etc. - Serious chronic diseases or progressive stage of a disease that cannot be steadily controlled, such as asthma, diabetes mellitus, thyroid disease, etc. - Congenital or acquired angioedema/angioneurotic edema. - Urticaria 1 year before receiving the candidate vaccine. - Asplenia or functional asplenia. - Thrombocytopenia or other coagulation disorders (which may contraindicate intramuscular injection). - Fear of needles. - Any immunosuppressant, antiallergic therapy, cytotoxic medicine, or inhaled corticosteroids (except corticosteroid spray for treatment of allergic rhinitis or corticosteroid treatment on surface for acute non-complicated dermatitis) in the past 6 months. - Blood products within 4 months prior to receiving the candidate vaccine. - Any other investigational medicine(s) within 1 month prior to the candidate vaccine. - Any live attenuated vaccine within 1 month prior to the candidate vaccine. - Any subunit vaccine or inactivated vaccine within 14 days prior to the candidate vaccine. - Receiving antituberculosis treatment. - Medical, psychological, social or other factors, which in the discretion of the investigators fail to meet the requirements in the trial protocol or affect the subjects to sign the ICFs. Exclusion criteria for the second/third dose: In this trial, the second/third vaccination may be stopped in some cases. They include systemic allergic reaction, severe hypersensitivity, or intolerable Grade 3 or above ARs after the previous dose of vaccine. If these reactions occur, the subjects should not continue to receive the second/third vaccination. |
Country | Name | City | State |
---|---|---|---|
China | Jiangsu Provincial Center for Disease Control and Prevention | Huai'an | Jiangsu |
Lead Sponsor | Collaborator |
---|---|
WestVac Biopharma Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The incidence of adverse reactions(ARs). | The incidence of ARs within 7 days after each vaccination. | Day 0 to day 7 | |
Primary | Anti-SARS-CoV-2 specific neutralizing antibodies expressed as geometric mean titer (GMT)and seroconversion rate (SCR). | The GMT and SCR of anti-SARS-CoV-2 specific neutralizing antibodies (euvirus) of the subjects on day 30 after the third vaccination. | Day 72 | |
Secondary | The incidence of ARs. | The incidence of ARs from Day 0 to Day 72. | Day 0 to Day 72 | |
Secondary | The incidence of adverse events (AEs). | The incidence of adverse events (AEs) from Day 0 to Day 72. | Day 0 to Day 72 | |
Secondary | The incidence of serious adverse events (SAEs). | The incidence of SAEs from day 0 through 6 months after the third vaccination. | Day 0 to 6 months after the third vaccination. | |
Secondary | The Geometric Mean Fold Increase (GMI) of the anti-SARS-COV-2 specific neutralizing antibody. | The GMI of the anti-SARS-COV-2 specific neutralizing antibody of the subjects on day 30 after the third vaccination. | Day 72 | |
Secondary | The Geometric Mean Titre (GMT), Seroconversion Rate (SCR) and GMI of anti-SARS-COV-2 S-RBD Immunoglobulin (IgG) antibody | The GMT, SCR and GMI of anti-SARS-COV-2 S-RBD IgG antibody of the subjects on day 30 after the third vaccination | Day 72 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|